Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Usana Health Sciences (USNA) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Usana Health Sciences (USNA) over the last 16 years, with Q3 2025 value amounting to 3.09%.

  • Usana Health Sciences' EBITDA Margin fell 117900.0% to 3.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.32%, marking a year-over-year decrease of 57400.0%. This contributed to the annual value of 3.87% for FY2024, which is 29600.0% down from last year.
  • According to the latest figures from Q3 2025, Usana Health Sciences' EBITDA Margin is 3.09%, which was down 117900.0% from 5.87% recorded in Q2 2025.
  • Over the past 5 years, Usana Health Sciences' EBITDA Margin peaked at 12.41% during Q3 2021, and registered a low of 3.09% during Q3 2025.
  • Over the past 5 years, Usana Health Sciences' median EBITDA Margin value was 5.87% (recorded in 2025), while the average stood at 5.96%.
  • Examining YoY changes over the last 5 years, Usana Health Sciences' EBITDA Margin showed a top increase of 42000bps in 2024 and a maximum decrease of -126400bps in 2024.
  • Usana Health Sciences' EBITDA Margin (Quarter) stood at 9.77% in 2021, then dropped by -10bps to 8.78% in 2022, then grew by 20bps to 10.54% in 2023, then tumbled by -120bps to 2.1% in 2024, then crashed by -47bps to 3.09% in 2025.
  • Its EBITDA Margin stands at 3.09% for Q3 2025, versus 5.87% for Q2 2025 and 3.73% for Q1 2025.